Omeros reports positive results from Phase II trial of OMS721 in thrombotic microangiopathy

US-based biopharmaceutical company Omeros has reported positive results from its ongoing Phase II clinical trial of OMS721 for the treatment of patients with hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HCT-TMA).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news